国产两女互慰高潮视频在线观看,无码人妻精品一二三区免费,亚洲av无码av制服另类专区,欧美一区二区三区成人片在线

首頁 > 產品目錄 > 信號通路 > Protein Tyrosine Kinase/RTK > c-Fms > Sotuletinib (BLZ945)

Sotuletinib (BLZ945)

ChemLeader 98+%

Sotuletinib (BLZ945)

產品編號:CL2550 CAS No.:953769-46-5 MDLNo: 分子式:C20H22N4O3S 分子量:398.48
規格 庫存 目錄價 會員專享價 數量
5 mg 3-5days ¥600.00 登錄后可見
- +
10 mg 3-5days ¥900.00 登錄后可見
- +
25 mg 3-5days ¥1600.00 登錄后可見
- +

化學品安全說明書(MSDS)

下載MSDS
  • 基本信息
  • 相關文檔
  • 產品詳情
  • 相關文獻
基本信息
英文名稱 Sotuletinib (BLZ945)
中文名稱Sotuletinib (BLZ945)
CAS號953769-46-5
分子式C20H22N4O3S
分子量398.48
外觀Off-white to light brown powder
儲存條件Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).
產品詳情

Sotuletinib (formerly BLZ945; BLZ-945) is a novel, potent, selective, orally bioactive, and brain-penetrant CSF-1R (colony stimulating factor 1 receptor) inhibitor with potential antitumor activity. It exhibits 1000-fold higher selectivity against its closest receptor tyrosine kinase homologs and inhibits CSF-1R with an IC50 of 1 nM. Glioma-bearing mice demonstrate high in vivo antitumor efficaciousness of BLZ945. Sotuletinib was designated as an orphan drug by the US FDA in August 2022 in order to treat patients suffering from Amyotrophic Lateral Sclerosis (ALS), a progressive neurological disorder that affects nerve cells in the brain and spinal cord and results in loss of motor control.

相關文獻
抱歉,暫時沒有相關文獻
相關產品
抱歉,暫時沒有相關產品
在線客服
小德
021-58180488
小立
021-58180488
在線服務時間: 工作日 9:00-18:00